The path to strategic manufacturing flexibility
by Sanofi Pasteur
Good decisions often translate into tremendous profits and market opportunities, while bad decisions can result in significant loss. Financial decision analysis techniques can pay long-term dividends, especially for biopharmaceutical executives who face technical and market uncertainties while developing products that are years away from commercialization. According to this white paper by Sanofi Pasteur, making multimillion-dollar investments in this type of environment requires an approach that not only helps quantify the risk associated with technology and market conditions, but also values the ability to be flexible in the staging and execution of investments.
This white paper explores how relatively new techniques such as real options analysis, Monte Carlo simulation and optimization models are beginning to gain ground in several more sophisticated biopharmaceutical companies. If used correctly, they can add a tremendous amount of value and insight into the strategic decision-making process.
| Published: | 2005 |
| Format: | |
| Length: | 9 pages |
| Type: | White paper |
| Language: | English |
.
SPONSORED REPORTS
